Shattuck Labs, Inc.
Shattuck Labs develops monoclonal and bispecific antibodies targeting DR3 for inflammatory and immune-mediated diseases.
SCHEDULE 13G/AAug 14Latest SEC filing
Aug 11Latest story
Sign inSign inShattuck Labs develops monoclonal and bispecific antibodies targeting DR3 for inflammatory and immune-mediated diseases.